A5103276242- Cancer Immunotherapy and Biomarkers
- Esophageal Cancer Research and Treatment
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Acute Myeloid Leukemia Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Gastric Cancer Management and Outcomes
- Lymphoma Diagnosis and Treatment
- Cancer-related molecular mechanisms research
- Adipokines, Inflammation, and Metabolic Diseases
- Inflammatory Biomarkers in Disease Prognosis
- Multiple Myeloma Research and Treatments
- Ferroptosis and cancer prognosis
- Cancer Research and Treatments
- Cancer, Lipids, and Metabolism
- Nonmelanoma Skin Cancer Studies
- Viral-associated cancers and disorders
- Cancer, Hypoxia, and Metabolism
- Monoclonal and Polyclonal Antibodies Research
- Gastroesophageal reflux and treatments
- Cancer Diagnosis and Treatment
- Gut microbiota and health
- Testicular diseases and treatments
- Chemokine receptors and signaling
- Cancer and Skin Lesions
Roswell Park Comprehensive Cancer Center
2018-2025
University of Oklahoma Health Sciences Center
2017-2019
University of Oklahoma
2017-2018
Oklahoma City University
2017
Background There is limited literature about the clinicopathological characteristics and outcomes of rare histologic variants gallbladder cancer (GBC). Methods Using SEER database, surgically managed GBC patients with microscopically confirmed adenocarcinoma, adenosquamous/squamous cell carcinoma papillary were identified from 1988 to 2009. Patients second primary distant metastasis at presentation excluded. The effect variables on overall survival (OS) disease specific (DSS) analyzed using...
Abstract Background Esophageal cancer (ESC) is an aggressive disease which often presents at advanced stage. Despite trimodal therapy, 40–50% patients can develop metastatic by 18 months. Identification of risk for spread challenging with need improved prognostication. We investigated whether the immune landscape pretreatment tissue was associated relapse in ESC patients. Methods Between April 2010 and October 2018, we identified 25 who had undergone therapy biopsies suitable analyses....
Camrelizumab combined with chemotherapy has shown significant clinical benefits in the first-line treatment of advanced esophageal squamous cell cancer (ESCC). Despite promising results from randomized trials, there is a need for real-world evidence to understand broader applicability and long-term outcomes neoadjuvant treatments diverse patient populations ESCC. This study aimed evaluate efficacy safety camrelizumab patients resectable locally ESCC setting. We retrospectively reviewed data...
Methylation-related regulators may be involved in the prognostic prediction of esophageal squamous cell carcinoma (ESCC). Our study aimed to apply bioinformatics screen methylation-related for construction a model patients with ESCC and assess their diagnostic value correlation immune infiltration. Prognosis-related genes were identified from The Cancer Genome Atlas (TCGA) database. Methylation-associated filtered using GeneCards We used least absolute shrinkage selection operator (LASSO)...
The prevalence of obesity, defined as the body mass index (BMI) ≥ 30 kg/m2, has reached epidemic levels. Obesity is associated with an increased risk various cancers, including gastrointestinal ones. Recent evidence suggested that obesity disproportionately impacts males and females cancer, resulting in varied transcriptional metabolic dysregulation. This study aimed to elucidate differences milieu adenocarcinomas (GI) tract both related unrelated sex obesity. To demonstrate these...
•We found diverse immune checkpoint co-expression patterns in GEAC.•We showed that elevated PD-L1 expression was linked with increased of other checkpoints.•This supports as a biomarker advanced GEAC for combination immunotherapy.•CD8 T-cell noted different checkpoints, pointing toward potential combined immunotherapy. BackgroundAddition immunotherapy to standard chemotherapy marginally improved outcomes gastroesophageal adenocarcinoma (GEAC). Recently, dual has shown efficacy melanoma and...
213 Background: Obesity has been previously investigated for its role in cancer and promoting tumor growth, at least partially by inducing a chronic inflammatory state. However, it’s unclear how this would play out the era of immunotherapy, where inflammation linked to treatment response. Albumin, marker nutritional status, is also negative marker. Patients with low albumin levels have known poor prognosis. In study, we aim assess association body mass index (BMI) level outcomes patients...
Khalid, Bilal MD; Mukherjee, Sarbajit Ibrahimi, Sami Cannon, Trinitia; Gilles, Elizabeth Moreau, Annie Razaq, Mohammad MD Author Information
124 Background: Microsatellite stable (MSS) colorectal cancer and CRCLM are highly resistant to current immunotherapeutic approaches. Understanding the TME impact of standard chemotherapeutics is utmost importance in developing optimal therapeutic strategies. Data limited on NACT TME. In this study, we sought explore effects chemotherapy proportions different immune cell populations [Total leukohematopoetic cells, CD45+, T markers, CD3+, CD8+, macrophage (M) CD163+, CD68+)], as well assess...
Mukherjee, Sarbajit; Ibrahimi, Sami; Scordino, Teresa; Cherry, Mohamad Author Information
413 Background: Fibrolamellar carcinoma (FLC) is a very rare liver tumor, comprising only 1% of all primary tumors in the United Sates. There no standard care for unresectable disease. Current practices are based on small retrospective studies and case series. We aim to analyze clinicopathologic factors treatment modalities affecting overall survival (OS) FLC. Methods: Using National Cancer Data Base (NCDB), we identified 496 patients diagnosed with FLC between 2004 2015. Simple descriptive...
Abstract Background: Liver metastases develop in 20-50% of colorectal cancer (CRC) patients, being typically resistant to immune checkpoint inhibitors (ICIs) and having a poor prognosis. Our preliminary data showed synergy between IFNα TLR3 ligands selectively enhancing the intratumoral production CD8+ T cell (CTL) attracting chemokines (but not Treg attractants) ex vivo-treated CRC explants preferential impact this combination on liver-metastatic tumor tissues (rather than surrounding liver...
4062 Background: Cetuximab is an EGFR-targeting IgG1 mAb. Pre-clinical data suggests cetuximab induces CD8 + cytotoxic T-cell (CTL) infiltration of tumors. We hypothesized that augmentation CTLs in the tumor microenvironment (TME) may provide proper milieu for effective PD-1 inhibition metastatic colorectal cancer (mCRC). conducted a phase Ib/II study with antibody, pembrolizumab, mCRC. Correlative blood and tissue samples were collected to assess impact this treatment on CTLs, as well...
<h3>Background</h3> Obesity is a major risk factor for the incidence and severity of multiple cancer types. Growing evidence indicate that obesity associated with dysregulation metabolism immunity. Leptin, hormone regulating hunger food intake, plays key role in development systemic metabolic dysregulation. Leptin has been identified as an inducer chronic inflammation promoting tumor growth, but its function inducing immunosuppressive TME poorly understood. <h3>Methods</h3> We used TCGA...